Markets
Stocks
Mutual Funds & ETF's
Sectors
Investing Tools
Overview
Market News
Analysts
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
Local Stocks
AFFYMAX (NQ: AFFY)
+0.3400 (+1.693%)
at
20.42
32,795 in Volume
Add to:
My Watchlist
Data as of 02:21 PM EST Feb 9,2010
Quote
Overview
Price and Volume
View Detailed Quote
chart
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
Today's Open 20.41
Bid (Size) 20.40 (300)
Ask (Size) 20.44 (300)
Prev. Close 20.08
Today's Range 19.86 - 20.67
52wk Range 11.79 - 25.64
Shares Outstanding 19,122,167
Morningstar Profile
View Full Profile
AFFYMAX
A biopharmaceutical company, which develops novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.
Healthcare
Biotechnology
Exchange Traded NQ
Market Cap 390.47M
Related Companies IPAR DPRM MAKO NBBTF
Top News
Read More
Affymax management to meet with Lazard Capital   
Feb 02, 2010
See the rest of the story here . Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other... Read More
category Conference/Events
from theflyonthewall.com
Affymax to Present at the 12th Annual BIO CEO & Investor Conference
Feb 01, 2010
from Business Wire News Releases
More News
Read More
Affymax (AFFY) Completes Hematide Phase 3   
Jan 25, 2010
from StreetInsider.com News Articles
Affymax completes treamtent and last patient follow up for Hematide   
Jan 25, 2010
category Hot Stocks
from theflyonthewall.com
Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide™, to Treat Anemia in Chronic Renal Failure
Jan 25, 2010
from Business Wire News Releases
Mid Cap Biotechs May Outperform In 2010   
Jan 15, 2010
category Biotechnology , AUXL , Cowen and Company , and 15 more.
from Benzinga
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Conference calls info supplied by OpenCompany
Fundamental data supplied by Morningstar
Stock quotes supplied by Telekurs USA
© Copyright FinancialContent, Inc.